Introducing the ENIVO™ System by AROA
AROA is thrilled to present groundbreaking findings from the first human study of its cutting-edge ENIVO platform. This research, documented in a peer-reviewed publication named Prospective, First-in-Human Clinical Evaluation of a Novel Tissue Apposition Device (ENIVO™) Following Simple Unilateral Mastectomy, was published in the prestigious journal Plastic and Reconstructive Surgery, Global Open.
Understanding Surgical Dead Space
When it comes to surgical procedures, particularly those involving soft tissue, a significant link to post-operative complications is the emergence of 'dead space'. This void occurs during surgical separation or excision and can collect seroma fluid, leading to various complications such as infections and extended recovery times.
How the ENIVO™ System Works
The innovative ENIVO device consists of a wearable vacuum pump attached to a tube and an Aroa ECM sleeve, implanted to facilitate healing at the surgical site. Its function is simple yet effective: it delivers suction to minimize dead space, remove excess fluid, and promote faster tissue healing. In a multi-center study that involved ten patients undergoing unilateral mastectomy, AROA showcased the effectiveness of the ENIVO system as an alternative to traditional surgical drains.
Limitations of Traditional Surgical Drains
Surgical drains, while commonly used, unfortunately, have several drawbacks. They can become blocked, leading to seroma formation, which occurs in 22-43% of mastectomy cases. This can delay healing, increase infection risks, and result in unsatisfactory aesthetic outcomes. AROA's ENIVO system addresses these issues head-on, aiming to reduce complications associated with surgical recovery.
Study Findings and Implications
The study, which observed patients for three months post-operation, reported impressive outcomes. The ENIVO device functioned as expected, with only one incident of seroma noted among participants. This successful performance highlights its potential to become a new standard in managing surgical dead space and elevating patient care.
Insights from AROA's Leadership
AROA's CEO, Brian Ward, expressed satisfaction about the study's publication, noting, "We're pleased to see this first ENIVO clinical study published. The results are promising, and it's pleasing to see the device has functioned exceptionally well in a procedure where complications have serious consequences for the patient's care." This confidence in the ENIVO system points towards a future with fewer complications and better patient outcomes.
Future Market Opportunities
AROA estimates that the market for the ENIVO system could exceed US$1B. Further developments and commercial activities are underway, with two out of three components of the ENIVO system already receiving FDA clearance, supporting AROA's ambition for widespread adoption.
About Aroa Biosurgery
Founded in 2008 and headquartered in Auckland, New Zealand, Aroa Biosurgery is dedicated to advancing soft tissue regeneration. The company aims to "unlock regenerative healing for every body" by creating, selling, and distributing surgical products to enhance healing in complex wound scenarios. Leveraging its proprietary AROA ECM technology, AROA has successfully launched four product families tailored for chronic wounds, hernia repair, soft tissue applications, and breast reconstruction, with over 7 million products used globally.
Frequently Asked Questions
What is the ENIVO™ system?
The ENIVO system is a device designed for managing surgical dead space, utilizing a vacuum pump to facilitate healing and prevent complications like seroma formation.
How does the ENIVO™ system compare to traditional drains?
Unlike traditional surgical drains, which can become blocked and fail, the ENIVO system uses vacuum technology to effectively manage post-surgical spaces, reducing the incidence of complications.
What were the results of the clinical study?
The study monitored ten patients and found that the ENIVO device performed well, with only one clinically relevant seroma occurring during the three-month postoperative period.
What is AROA Biosurgery's mission?
AROA Biosurgery is focused on improving healing through innovative technologies, aiming to enhance recovery outcomes for patients with complex wounds and in surgical settings.
Where is AROA based and listed?
AROA is headquartered in Auckland, New Zealand, and is publicly traded on the Australian Securities Exchange under the ticker ASX: ARX.
